Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 5, Issue 1, 2023

Research Progress on the Mechanism of Traditional Chinese Medicine in the Treatment of Non-Alcoholic Fatty Liver Disease Based on Oxidative Stress

Download as PDF

DOI: 10.23977/medcm.2023.050105 | Downloads: 13 | Views: 517

Author(s)

Xinyi Li 1, Jianping Xi 2, Haitao Liu 2, Lingna Jia 1, Huayi Zhang 1

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, 712046, China
2 Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, 712046, China

Corresponding Author

Jianping Xi

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) accounts for an increasing proportion of liver diseases, but its pathogenesis is more complex, and there is no more effective clinical treatment. Oxidative stress is considered to be an important factor leading to the progression of NAFLD. Therefore, improving the oxidative stress status of NAFLD patients is of great significance for the prevention and treatment of the disease. In recent years, a number of experimental studies have shown that traditional Chinese medicine has unique advantages in the treatment of various clinical diseases, and domestic and foreign researches on the treatment of NAFLD with traditional Chinese medicine are also emerging one after another. Based on this, this paper summarizes the mechanism of some traditional Chinese medicine, traditional Chinese medicine compound and Chinese patent medicine on oxidative stress in the development of NAFLD, in order to provide new ideas for clinical treatment of NAFLD.

KEYWORDS

Nonalcoholic fatty liver disease, Traditional Chinese medicine, Chinese medicine compound, Chinese patent medicine, Oxidative stress, Research progress

CITE THIS PAPER

Xinyi Li, Jianping Xi, Haitao Liu, Lingna Jia, Huayi Zhang, Research Progress on the Mechanism of Traditional Chinese Medicine in the Treatment of Non-Alcoholic Fatty Liver Disease Based on Oxidative Stress. MEDS Chinese Medicine (2023) Vol. 5: 32-39. DOI: http://dx.doi.org/10.23977/medcm.2023.050105.

REFERENCES

[1] Li J, Chen J, Wang Y. Consensus opinion on the diagnosis and treatment of non-alcoholic fatty liver disease in the integrative medicine (2017) [J]. chinese journal of integrated traditional and western medicine on digestion, 2017, 25(11): 805-811. 
[2] Anstee Q M,Reeves H L，Kotsiliti E , et al. From NASH to HCC: current concepts and future challenges [J]. Nature Reviews Gastroenterology & Hepatology, 2019, 16(7): 411-428.
[3] Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalc- oholic Steatohepatitis [J]. Hepatology, 2019, 69(6): 2672-2682.
[4] XU Y, Fan J. Research progress of therapeutic drugs for non-alcoholic fatty liver disease [J]. Shanghai Medicine, 2020, 41(19): 3-11.
[5] Forrester S J, Kikuchi D S, Hernandes M S, et al. Reactive Oxygen Species in Metabolic and Inflammatory Signaling [J]. Circulation Research, 2018, 122(6): 877-902.
[6] James O, Day C P. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance [J]. Journal of Hepatology, 1998, 29(3): 495-501.
[7] Oyewole A O, Mark A. Birch-Machin. Mitochondria-targeted antioxidants [J]. The FASEB Journal, 2015, 29(12): 4766-4771.
[8] Buzzetti E, Pinzani M, Tsochatzis E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J]. Metabolism-clinical & Experimental, 2016; 65(8): 1038-1048.
[9] Hu Q, Zhang W, Wu Z, et al. Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects [J]. Pharmacological Research, 2021, 165(1): 105444.
[10] Zhong X, Liu H. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways [J]. Biomedicine & Pharmacotherapy, 2018, 98: 111-117.
[11] Caro A A, Cederbaum A I. Oxidative Stress, Toxicology, and Pharmacology of CYP2E1 [J]. Annual Review of Pharmacology, 2004, 44(1): 27-42.
[12] Gao W, Xu B, Zhang Y, et al. Baicalin Attenuates Oxidative Stress in a Tissue-Engineered Liver Model of NAFLD by Scavenging Reactive Oxygen Species [J]. Nutrients, 2022, 14(3): 541.
[13] Kong T, Ma Y, Yang Z,et al. Biological function and action mechanism of resveratrol [J]. China Journal of Clinical Pharmacology, 2022, 38(06): 59 2-596.
[14] Cheng K, Song Z, Zhang H, et al. The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression [J]. Medical electron microscopy, 2019, 52(4): 187-197.
[15] Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease [J]. Archives of Physiology and Biochemistry, 2019, 125(2): 142-149.
[16] GAI X, Liu S, Ren T, et al. Research progress on chemical constituents and pharmacological action of Rhizoma Coptidis [J]. Chinese Herbal Medicine, 2018, 49(20): 4919- 4927.
[17] FU L, FU Q, LI J, et al. Research progress on chemical constituents and pharmacological action of Rhizoma Coptidis [J]. Journal of Traditional Chinese Medicine, 2021, 49(02): 87-92.
[18] Sun Y, Yuan X, Zhang F, et al. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells [J]. Scientific Reports, 2017, 7(1):11340.
[19] Zhang Y, Wen J, Liu D, et al. Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice [J]. Life Sciences, 2021, (16): 119778.
[20] Ming H, Sha L, Ning W, et al. A Biomedical Investigation of the Hepatoprotective Effect of Radix salviae miltiorrhizae and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets [J]. International Journal of Molecular Sciences, 2017, 18(3): 620.
[21] Zhou L, Tang J, Yang X, et al. Five Constituents in Psoralea corylifolia L. Attenuate Palmitic Acid-Induced Hepatocyte Injury via Inhibiting the Protein Kinase C-α/Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Pathway [J]. Frontiers in pharmacology, 2019, 10: 1589-1589.
[22] He W, Xu Y, Zhang C, et al. Hepatoprotective effect of calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes [J]. Drug Design, Development and Therapy, 2017, 11: 3449-3460.
[23] Ahmed SM, Luo L, Namani A, et al. Nrf2 signaling pathway: Pivotal roles in inflammation [J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(2): 585-597.
[24] Copple I M, Goldring C E, Kitteringham N R, et al. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity [J]. Toxicology, 2008, 246(1): 24-33.
[25] Gupte AA, Lyon CJ, Hsueh WA. Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis [J]. Curr Diab Rep. 2013; 13(3): 362-371.
[26] Sokolovic D, Nikolic J, Kocic G, et al. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation [J]. Drug & Chemical Toxicology, 2013, 36(2): 141-148.
[27] Gentile C L, Nivala A M, Gonzales J C, et al. Experimental evidence for therapeutic potential of taurine in the treatment of non-alcoholic fatty liver disease [J]. Ajp Regulatory Integrative & Comparative Physiology, 2011, 301(6): R1710-R1722.
[28] Yang XX, Wang X, Shi TT, et al. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum [J]. Biomed Pharmacother. 2019; 117: 109083.
[29] Xu L, Jing M, Yang L, et al. The Alisma and Rhizoma decoction abates nonalcoholic steatohepatitisassociated liver injuries in mice by modulating oxidative stress and autophagy [J]. BMC Complement Altern Med, 2019, 19(1): 92．
[30] Li K, Wu D, Chen X, et al. Current and emerging biomarkers of cell death in human disease [J]. Biomed Res Int. 2014; 2014: 690103.
[31] Zhou F, Peng J, Fan F, et al. The relationship between autophagy and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease [J]. Journal of Clinical Hepatobiliary Disease, 2018, 34(08): 1805-1808.
[32] Zhang S, Li J. Expert consensus on diagnosis and treatment of non-alcoholic fatty liver disease in traditional Chinese medicine (2017) [J]. Journal of Clinical Hepatobiliary Disease, 2017, 33(12): 2270-2274.
[33] Tu G, Gong X, Yang Q, et al. Effects of extracts from soothing-liver and invigorating-spleen formulas on the injury induced by oxidative stress in the hepatocytes of rats with non-alcoholic fatty liver disease induced by high-fat diet [J]. Journal of Traditional Chinese Medicine, 2018.
[34] Zhou X, Tang N, Zack Z, et al. Exploration of the mechanism of Lizhong Decoction in the treatment of non-alcoholic steatohepatitis based on IKK/IKB/NF-κB signaling pathway [J]. Chinese Journal of Traditional Chinese Medicine, 2020, 35(06): 2771-2777.
[35] Liu J, Kan D, Liu L. Blocking of IKK/IκB/NF-κB signaling pathway and its clinical application [J]. Journal of Practical Medicine, 2008, 24(23): 4147-4149.
[36] Sun K, Xu L, Jing Y, et al. Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α/β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis [J]. Cancer Letters, 2017, 388: 198-207.
[37] Zeng J, Liu XL, Xin FZ, et al. Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high-fat, high-cholesterol diet [J]. J Dig Dis, 2020, 21(3): 179-188.
[38] Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases [J]. Gastroenterology, 2018, 155(3): 629-647.
[39] Begriche K, Massart J, Robin MA,,et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease [J]. Hepatology, 2013, 58(4): 1497-1507.
[40] Wang X, Li J, Miao Y. Effect observation of Dangfeiliganning capsule combined with life intervention in the treatment of non-alcoholic fatty liver [J]. Journal of Chengdu University of Chinese Medicine, 2013, 36(03): 69-70+78.
[41] Hong H, Zhao X, Zhang S, et al. Clinical observation on 37 cases of non-alcoholic fatty liver with syndrome of liver stagnation and spleen deficiency and damp heat accumulation treated with Dangfeiliganning capsule and Chinese medicine tea [J]. journal of traditional chinese medicine, 2018, 59(03): 227-230.
[42] Zhao H, Chen W, Jiang L. Effect of Dangfeiliganning capsule on antioxidant system in patients with chronic hepatitis B [J]. journal of traditional chinese medicine, 2007(05): 466.
[43] Zhao Y, Shu X, Yang Z, et al. Study on the mechanism of Dangfeiliganning capsule in regulating liver oxidative stress and improving non-alcoholic fatty liver disease in mice [J]. Journal of Shanghai University of Traditional Chinese Medicine, 2021, 35(05): 37-43+74. 

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4203
Visits: 165808

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.